Patienterne have aldrig oplevet virologisk svigt i forbindelse med tidligere antiretroviral behandling, havde ingen kendte HIV- 1- mutationer, som giver resistens over for en eller flere af komponenterne i Atripla og havde været virologisk supprimeret i mindst tre måneder ved baseline.
Patients had never experienced virological failure on a previous antiretroviral therapy, had no known HIV-1 mutations that confer resistance to any of the three components within Atripla, and had been virologically suppressed for at least three months at baseline.